脳インプラント市場の2032年までの予測：製品別、用途別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、脳インプラントの世界市場は2025年に74億米ドルを占め、予測期間中にCAGR11.9％で成長し、2032年までには162億6,000万米ドルに達する見込みです。

脳インプラントとして知られる先進医療機器は、脳に直接挿入されることで、神経組織とのコミュニケーションを促進します。これらのインプラントには、数多くの治療、診断、強化用途が存在します。インプラントは、電極を介して電気信号を送受信することで、脳の活動を捕捉したり、誘発したりします。脳インプラントの安全性、機能性、可能な用途は、材料科学、ワイヤレス技術、機械学習における最近の動向によって大きく向上しています。

米国神経外科学会（AANS）によると、米国では約25万人がジストニア（不随意筋収縮を特徴とする神経学的運動障害）に罹患しています。

神経疾患の有病率の増加

神経疾患の有病率は、世界中で驚くべき速さで増加しています。世界中で何百万人もの人々が、てんかん、パーキンソン病、アルツハイマー病、慢性疼痛、うつ病など、なかなか治らない症状に苦しんでいます。例えば、世界保健機関（WHO）の推計によると、世界中で5,000万人以上がてんかんを患っています。異常な神経活動を制御し、患者の生活の質を高めることで、脳インプラントは効率的な介入を提供します。さらに、従来の治療では、特に患者が薬剤抵抗性の場合、しばしば失敗するため、植え込み型神経刺激装置の必要性は高まっています。

高価な手技と機器

脳深部刺激（DBS）システムやその他の脳インプラントは高額であり、手術費用や術後費用を考慮しなければ、患者1人当たり35,000ドルから50,000ドルの費用がかかります。特に中低所得国では、初期費用と継続費用が高額になることが、利用を妨げる重要な障害となっています。先進国であっても保険適用が制限されている場合があり、このことが患者がこのような治療を選択することを躊躇させています。さらに、特に長期的なモニタリング、機器の維持管理、調整が必要となる可能性のある問題などを考慮すると、費用負担はヘルスケアシステムにも影響します。

BCI（ブレインコンピュータインターフェース）の成長

ブレインコンピュータインターフェース（BCI）は、脳インプラントと外部コンピューティングシステムを統合するもので、ヘルスケアやその他の分野で革命的な可能性を開いています。ブレインコンピュータインターフェース（BCI）を使うことで、手足を失った人や麻痺した人は、神経信号を使ってコンピューターや車椅子、義肢を操作できるようになります。シンクロンの血管内BCIやイーロン・マスクのNeuralinkのような取り組みは、治療と非医療の両分野で使用するための関心と資金を集めています。さらに、これらの技術が発展し、コミュニケーション、ゲーム、スマートデバイス、拡張認知などの分野で商業利用されるようになれば、脳インプラントの市場は従来の医療現場以外でも大きく拡大する可能性があります。

倫理的反発と一般市民の懐疑心

技術的な可能性があるにもかかわらず、倫理的・哲学的な問題から、世間はいまだに脳インプラントに懐疑的です。擁護団体や患者は、マインドコントロールされ、自律性を失い、人格が変化するような人物を受け入れるのは難しいと考えるかもしれません。宗教的あるいは文化的な理由から、人間の脳の神聖さが非常に重視される社会では、侵襲的な処置はしばしば抵抗されます。さらに、脳インプラントが機能強化と治療を混同し始めると、倫理的境界や乱用の可能性に関する議論が高まり、その結果、市場によっては規制や禁止がなされることもあります。

COVID-19の影響：

COVID-19の大流行は、脳インプラント市場にさまざまな影響を与えました。当初の市場の混乱には、サプライチェーンの混乱、病院の収容能力の低下、選択的脳神経外科手術の延期などの結果、インプラント手術や臨床試験が一時的に減少したことが含まれます。しかし、ヘルスケアシステムが患者の遠隔モニタリングや慢性疾患管理のための最先端ソリューションに注目する中、パンデミックは神経技術やデジタルヘルスへの投資も加速させました。さらに、脳霧、脳卒中、認知機能障害など、COVIDの長期化に関連した神経学的合併症の有病率の増加により、長期的な市場成長も見込まれています。

予測期間中、脳深部刺激装置（DBS）分野が最大となる見込み

予測期間中、脳深部刺激装置（DBS）分野が最大の市場シェアを占めると予想されます。DBSは、パーキンソン病、本態性振戦、ジストニア、強迫性障害などの神経疾患の治療に臨床的に成功し、広く使用されていることから、最も広く使用されている神経調節療法です。この治療法では、脳の特定部位に電極を埋め込み、制御された電気インパルスを流すことで、異常な神経活動を効果的に調節します。さらに、FDA承認済みで、確立されており、豊富な臨床データに支えられており、装置の小型化、バッテリー寿命、MRI適合性において技術革新が進んでいるため、その採用はさらに進んでいます。

予測期間中、うつ病分野のCAGRが最も高くなる見込み

予測期間中、うつ病分野は、神経調節療法が受け入れられつつあることと、治療抵抗性うつ病（TRD）の罹患率が上昇していることから、最も高い成長率を示すと予測されます。脳深部刺激療法（DBS）や迷走神経刺激療法（VNS）は、従来の抗うつ薬に代わる有効な治療法になりつつあります。現在進行中の臨床試験や、気分調節のために設計された閉ループシステムの開発により、埋め込み型ソリューションへの関心が高まっています。さらに、COVID-19パンデミックによる精神衛生危機の悪化は、新規治療の必要性を浮き彫りにし、この急速に拡大する分野への投資と研究に拍車をかけています。

最大のシェアを占める地域

予測期間中、北米地域が最大の市場シェアを占めると予想されますが、その大部分は米国が牽引しており、世界市場の収益に大きく貢献しています。高いヘルスケア支出、洗練された医療インフラ、うつ病、てんかん、パーキンソン病などの神経疾患の罹患率の増加など、すべてがこの地域に利益をもたらしています。北米の優位性は、トップ企業の存在、有利な償還慣行、進行中の研究開発イニシアティブにも起因しています。さらに、この地域の市場拡大を促進し、世界の主要プレーヤーとしての地位を確立しているのは、脳インプラントに対する認知度の高まりと、長期的な神経疾患の治療におけるその有効性です。

CAGRが最も高い地域：

予測期間中、アジア太平洋が最も高いCAGRを示すと予測されます。これは、神経疾患の発生率の上昇、投資の増加、ヘルスケアインフラの迅速な改善などが背景にあります。中国、インド、日本などの国々では、人口の高齢化、脳の健康に対する意識の高まり、ヘルスケアへのアクセスの容易さなどの結果、最先端の医療技術に対するニーズが高まっています。ヘルスケアシステムの改善を目的とした政府のプログラムや投資も、市場の拡大を後押ししています。さらに、この地域は患者人口が多く、可処分所得が増加しているため、今後の成長が非常に有望な市場であり、脳インプラント技術の採用にも影響を与えています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査情報源
  • 1次調査情報源
  • 2次調査情報源
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• 用途分析
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の脳インプラント市場：製品別

• 脳深部刺激装置
• 迷走神経刺激
• 応答性神経刺激

第6章 世界の脳インプラント市場：用途別

• 慢性疼痛
• てんかん
• パーキンソン病
• うつ
• アルツハイマー病
• 本態性振戦
• その他の用途

第7章 世界の脳インプラント市場：エンドユーザー別

• 病院
• 神経科クリニック
• その他のエンドユーザー

第8章 世界の脳インプラント市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東・アフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、ジョイントベンチャー
• 買収と合併
• 新製品発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイリング

• Boston Scientific Corporation
• Medtronic plc
• Synchron Inc.
• Abbott Laboratories
• NeuroPace, Inc.
• LivaNova Plc
• Precision Neuroscience Inc
• NDI Medical LLC
• Renishaw PLC
• Aleva Neurotherapeutics SA
• Beijing PINS Medical Co., Ltd
• Functional Neuromodulation, Ltd.
• SceneRay Co., Ltd
• Cyberonics, Inc.
• NeuroSigma Inc

List of Tables

• Table 1 Global Brain Implants Market Outlook, By Region (2024-2032) ($MN)
• Table 2 Global Brain Implants Market Outlook, By Product (2024-2032) ($MN)
• Table 3 Global Brain Implants Market Outlook, By Deep Brain Stimulator (2024-2032) ($MN)
• Table 4 Global Brain Implants Market Outlook, By Vagus Nerve Stimulation (2024-2032) ($MN)
• Table 5 Global Brain Implants Market Outlook, By Responsive Neurostimulation (2024-2032) ($MN)
• Table 6 Global Brain Implants Market Outlook, By Application (2024-2032) ($MN)
• Table 7 Global Brain Implants Market Outlook, By Chronic Pain (2024-2032) ($MN)
• Table 8 Global Brain Implants Market Outlook, By Epilepsy (2024-2032) ($MN)
• Table 9 Global Brain Implants Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
• Table 10 Global Brain Implants Market Outlook, By Depression (2024-2032) ($MN)
• Table 11 Global Brain Implants Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
• Table 12 Global Brain Implants Market Outlook, By Essential Tremor (2024-2032) ($MN)
• Table 13 Global Brain Implants Market Outlook, By Other Applications (2024-2032) ($MN)
• Table 14 Global Brain Implants Market Outlook, By End User (2024-2032) ($MN)
• Table 15 Global Brain Implants Market Outlook, By Hospitals (2024-2032) ($MN)
• Table 16 Global Brain Implants Market Outlook, By Neurology Clinics (2024-2032) ($MN)
• Table 17 Global Brain Implants Market Outlook, By Other End Users (2024-2032) ($MN)
• Table 18 North America Brain Implants Market Outlook, By Country (2024-2032) ($MN)
• Table 19 North America Brain Implants Market Outlook, By Product (2024-2032) ($MN)
• Table 20 North America Brain Implants Market Outlook, By Deep Brain Stimulator (2024-2032) ($MN)
• Table 21 North America Brain Implants Market Outlook, By Vagus Nerve Stimulation (2024-2032) ($MN)
• Table 22 North America Brain Implants Market Outlook, By Responsive Neurostimulation (2024-2032) ($MN)
• Table 23 North America Brain Implants Market Outlook, By Application (2024-2032) ($MN)
• Table 24 North America Brain Implants Market Outlook, By Chronic Pain (2024-2032) ($MN)
• Table 25 North America Brain Implants Market Outlook, By Epilepsy (2024-2032) ($MN)
• Table 26 North America Brain Implants Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
• Table 27 North America Brain Implants Market Outlook, By Depression (2024-2032) ($MN)
• Table 28 North America Brain Implants Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
• Table 29 North America Brain Implants Market Outlook, By Essential Tremor (2024-2032) ($MN)
• Table 30 North America Brain Implants Market Outlook, By Other Applications (2024-2032) ($MN)
• Table 31 North America Brain Implants Market Outlook, By End User (2024-2032) ($MN)
• Table 32 North America Brain Implants Market Outlook, By Hospitals (2024-2032) ($MN)
• Table 33 North America Brain Implants Market Outlook, By Neurology Clinics (2024-2032) ($MN)
• Table 34 North America Brain Implants Market Outlook, By Other End Users (2024-2032) ($MN)
• Table 35 Europe Brain Implants Market Outlook, By Country (2024-2032) ($MN)
• Table 36 Europe Brain Implants Market Outlook, By Product (2024-2032) ($MN)
• Table 37 Europe Brain Implants Market Outlook, By Deep Brain Stimulator (2024-2032) ($MN)
• Table 38 Europe Brain Implants Market Outlook, By Vagus Nerve Stimulation (2024-2032) ($MN)
• Table 39 Europe Brain Implants Market Outlook, By Responsive Neurostimulation (2024-2032) ($MN)
• Table 40 Europe Brain Implants Market Outlook, By Application (2024-2032) ($MN)
• Table 41 Europe Brain Implants Market Outlook, By Chronic Pain (2024-2032) ($MN)
• Table 42 Europe Brain Implants Market Outlook, By Epilepsy (2024-2032) ($MN)
• Table 43 Europe Brain Implants Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
• Table 44 Europe Brain Implants Market Outlook, By Depression (2024-2032) ($MN)
• Table 45 Europe Brain Implants Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
• Table 46 Europe Brain Implants Market Outlook, By Essential Tremor (2024-2032) ($MN)
• Table 47 Europe Brain Implants Market Outlook, By Other Applications (2024-2032) ($MN)
• Table 48 Europe Brain Implants Market Outlook, By End User (2024-2032) ($MN)
• Table 49 Europe Brain Implants Market Outlook, By Hospitals (2024-2032) ($MN)
• Table 50 Europe Brain Implants Market Outlook, By Neurology Clinics (2024-2032) ($MN)
• Table 51 Europe Brain Implants Market Outlook, By Other End Users (2024-2032) ($MN)
• Table 52 Asia Pacific Brain Implants Market Outlook, By Country (2024-2032) ($MN)
• Table 53 Asia Pacific Brain Implants Market Outlook, By Product (2024-2032) ($MN)
• Table 54 Asia Pacific Brain Implants Market Outlook, By Deep Brain Stimulator (2024-2032) ($MN)
• Table 55 Asia Pacific Brain Implants Market Outlook, By Vagus Nerve Stimulation (2024-2032) ($MN)
• Table 56 Asia Pacific Brain Implants Market Outlook, By Responsive Neurostimulation (2024-2032) ($MN)
• Table 57 Asia Pacific Brain Implants Market Outlook, By Application (2024-2032) ($MN)
• Table 58 Asia Pacific Brain Implants Market Outlook, By Chronic Pain (2024-2032) ($MN)
• Table 59 Asia Pacific Brain Implants Market Outlook, By Epilepsy (2024-2032) ($MN)
• Table 60 Asia Pacific Brain Implants Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
• Table 61 Asia Pacific Brain Implants Market Outlook, By Depression (2024-2032) ($MN)
• Table 62 Asia Pacific Brain Implants Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
• Table 63 Asia Pacific Brain Implants Market Outlook, By Essential Tremor (2024-2032) ($MN)
• Table 64 Asia Pacific Brain Implants Market Outlook, By Other Applications (2024-2032) ($MN)
• Table 65 Asia Pacific Brain Implants Market Outlook, By End User (2024-2032) ($MN)
• Table 66 Asia Pacific Brain Implants Market Outlook, By Hospitals (2024-2032) ($MN)
• Table 67 Asia Pacific Brain Implants Market Outlook, By Neurology Clinics (2024-2032) ($MN)
• Table 68 Asia Pacific Brain Implants Market Outlook, By Other End Users (2024-2032) ($MN)
• Table 69 South America Brain Implants Market Outlook, By Country (2024-2032) ($MN)
• Table 70 South America Brain Implants Market Outlook, By Product (2024-2032) ($MN)
• Table 71 South America Brain Implants Market Outlook, By Deep Brain Stimulator (2024-2032) ($MN)
• Table 72 South America Brain Implants Market Outlook, By Vagus Nerve Stimulation (2024-2032) ($MN)
• Table 73 South America Brain Implants Market Outlook, By Responsive Neurostimulation (2024-2032) ($MN)
• Table 74 South America Brain Implants Market Outlook, By Application (2024-2032) ($MN)
• Table 75 South America Brain Implants Market Outlook, By Chronic Pain (2024-2032) ($MN)
• Table 76 South America Brain Implants Market Outlook, By Epilepsy (2024-2032) ($MN)
• Table 77 South America Brain Implants Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
• Table 78 South America Brain Implants Market Outlook, By Depression (2024-2032) ($MN)
• Table 79 South America Brain Implants Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
• Table 80 South America Brain Implants Market Outlook, By Essential Tremor (2024-2032) ($MN)
• Table 81 South America Brain Implants Market Outlook, By Other Applications (2024-2032) ($MN)
• Table 82 South America Brain Implants Market Outlook, By End User (2024-2032) ($MN)
• Table 83 South America Brain Implants Market Outlook, By Hospitals (2024-2032) ($MN)
• Table 84 South America Brain Implants Market Outlook, By Neurology Clinics (2024-2032) ($MN)
• Table 85 South America Brain Implants Market Outlook, By Other End Users (2024-2032) ($MN)
• Table 86 Middle East & Africa Brain Implants Market Outlook, By Country (2024-2032) ($MN)
• Table 87 Middle East & Africa Brain Implants Market Outlook, By Product (2024-2032) ($MN)
• Table 88 Middle East & Africa Brain Implants Market Outlook, By Deep Brain Stimulator (2024-2032) ($MN)
• Table 89 Middle East & Africa Brain Implants Market Outlook, By Vagus Nerve Stimulation (2024-2032) ($MN)
• Table 90 Middle East & Africa Brain Implants Market Outlook, By Responsive Neurostimulation (2024-2032) ($MN)
• Table 91 Middle East & Africa Brain Implants Market Outlook, By Application (2024-2032) ($MN)
• Table 92 Middle East & Africa Brain Implants Market Outlook, By Chronic Pain (2024-2032) ($MN)
• Table 93 Middle East & Africa Brain Implants Market Outlook, By Epilepsy (2024-2032) ($MN)
• Table 94 Middle East & Africa Brain Implants Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
• Table 95 Middle East & Africa Brain Implants Market Outlook, By Depression (2024-2032) ($MN)
• Table 96 Middle East & Africa Brain Implants Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
• Table 97 Middle East & Africa Brain Implants Market Outlook, By Essential Tremor (2024-2032) ($MN)
• Table 98 Middle East & Africa Brain Implants Market Outlook, By Other Applications (2024-2032) ($MN)
• Table 99 Middle East & Africa Brain Implants Market Outlook, By End User (2024-2032) ($MN)
• Table 100 Middle East & Africa Brain Implants Market Outlook, By Hospitals (2024-2032) ($MN)
• Table 101 Middle East & Africa Brain Implants Market Outlook, By Neurology Clinics (2024-2032) ($MN)
• Table 102 Middle East & Africa Brain Implants Market Outlook, By Other End Users (2024-2032) ($MN)

According to Stratistics MRC, the Global Brain Implants Market is accounted for $7.40 billion in 2025 and is expected to reach $16.26 billion by 2032 growing at a CAGR of 11.9% during the forecast period. Advanced medical devices known as brain implants, when inserted directly into the brain, facilitate communication with neural tissue. Numerous therapeutic, diagnostic, and enhancement applications exist for these implants. They work by capturing or triggering brain activity, frequently by sending and receiving electrical signals via electrodes. The safety, functionality, and possible uses of brain implants have been greatly enhanced by recent developments in materials science, wireless technology, and machine learning.

According to the American Association of Neurological Surgeons (AANS), approximately 250,000 individuals in the U.S. are affected by dystonia, a neurological movement disorder characterized by involuntary muscle contractions.

Market Dynamics:

Driver:

Increasing neurological disorder prevalence

The prevalence of neurological disorders is rising at a startling rate worldwide. Millions of people worldwide suffer from conditions like epilepsy, Parkinson's disease, Alzheimer's, chronic pain, and depression that don't go away. For example, according to estimates from the World Health Organization (WHO), more than 50 million people worldwide have epilepsy. By controlling aberrant neural activity and enhancing patients' quality of life, brain implants provide an efficient intervention. Moreover, the need for implantable neurostimulation devices is growing since traditional treatments frequently fail, particularly in cases where the patient is drug-resistant.

Restraint:

Expensive procedures and equipment

Deep brain stimulation (DBS) systems and other brain implants are costly; without accounting for surgical and postoperative costs, they can cost anywhere from $35,000 to $50,000 per patient. An important obstacle to access is the high initial and ongoing costs, especially in low- and middle-income nations. Insurance coverage may be restricted, even in developed areas, which deters patients from choosing such treatments. Additionally, the cost burden also affects healthcare systems, particularly when long-term monitoring, device upkeep, and possible issues necessitating adjustments are taken into account.

Opportunity:

Growth of BCIs (brain-computer interfaces)

Brain-computer interfaces (BCIs) are integrating brain implants with external computing systems, opening up revolutionary possibilities in healthcare and other fields. Through the use of brain-computer interfaces (BCIs), people who have lost limbs or are paralyzed can use neural signals to operate computers, wheelchairs, and prosthetic limbs. Initiatives like Synchron's endovascular BCIs and Elon Musk's Neuralink are garnering interest and funding for use in both therapeutic and non-medical fields. Furthermore, the market for brain implants may be greatly expanded outside of traditional medical settings as these technologies develop and find commercial use in communication, gaming, smart devices, and augmented cognition.

Threat:

Ethical backlash and public skepticism

The public is still skeptical of brain implants despite their technological potential because of ethical and philosophical issues. Advocacy groups and patients may find it difficult to accept someone who has mind control, loses autonomy, or changes their personality. In societies where the sanctity of the human brain is highly valued for religious or cultural reasons, invasive procedures are frequently resisted. Moreover, as brain implants start to conflate enhancement and treatment, there is growing discussion about ethical boundaries and possible abuse, which may result in restrictions or prohibitions in some markets.

Covid-19 Impact:

The COVID-19 pandemic affected the market for brain implants in a variety of ways. Initial market disruptions included a temporary drop in implant procedures and clinical trials as a result of supply chain disruptions, hospital capacity reductions, and the postponement of elective neurosurgeries. However, as healthcare systems looked into cutting-edge solutions for remote patient monitoring and chronic disease management, the pandemic also accelerated investments in neuro-technology and digital health. Additionally, long-term market growth is also anticipated due to the increased prevalence of neurological complications linked to prolonged COVID, such as brain fog, stroke, and cognitive dysfunction.

The deep brain stimulator (DBS) segment is expected to be the largest during the forecast period

The deep brain stimulator (DBS) segment is expected to account for the largest market share during the forecast period. DBS is the most widely used neuromodulation therapy, driven by its clinical success and widespread use in treating neurological disorders like Parkinson's disease, essential tremor, dystonia, and obsessive-compulsive disorder. It involves the implantation of electrodes in specific brain regions to deliver controlled electrical impulses, effectively modulating abnormal neural activity. Furthermore, it is FDA-approved, well-established, and supported by a wealth of clinical data, and its adoption is further enhanced by ongoing innovation in device miniaturization, battery life, and MRI compatibility.

The depression segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the depression segment is predicted to witness the highest growth rate, driven by the growing acceptance of neuromodulation therapies and the rising incidence of treatment-resistant depression (TRD). Deep brain stimulation (DBS) and vagus nerve stimulation (VNS) are becoming viable substitutes for traditional antidepressants, which frequently fail to relieve a considerable percentage of patients. Interest in implantable solutions is being fueled by ongoing clinical trials and developments in closed-loop systems designed for mood regulation. Additionally, the COVID-19 pandemic's worsening of the mental health crisis has highlighted the need for novel treatments, spurring investment and research in this rapidly expanding field.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, mostly driven by the United States, which contributes significantly to global market revenue. High healthcare spending, a sophisticated healthcare infrastructure, and an increasing incidence of neurological conditions like depression, epilepsy, and Parkinson's disease all benefit the area. The dominance of North America is also attributed to the existence of top businesses, advantageous reimbursement practices, and ongoing R&D initiatives. Furthermore, driving market expansion in this area and establishing it as a major player globally is growing awareness of brain implants and their effectiveness in treating long-term neurological disorders.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by the rising incidence of neurological disorders, growing investments, and quick improvements in healthcare infrastructure. The need for cutting-edge medical technologies is rising in nations like China, India, and Japan as a result of aging populations, growing awareness of brain health, and easier access to healthcare. Government programs and investments meant to improve healthcare systems also encourage market expansion. Moreover, the region is a very promising market for future growth because of its large patient population and growing disposable incomes, which are also influencing the adoption of brain implant technologies.

Key players in the market

Some of the key players in Brain Implants Market include Boston Scientific Corporation, Medtronic plc, Synchron Inc., Abbott Laboratories, NeuroPace, Inc., LivaNova Plc, Precision Neuroscience Inc, NDI Medical LLC, Renishaw PLC, Aleva Neurotherapeutics SA, Beijing PINS Medical Co., Ltd, Functional Neuromodulation, Ltd., SceneRay Co., Ltd, Cyberonics, Inc. and NeuroSigma Inc.

Key Developments:

In April 2025, Medtronic plc announced a strategic agreement to distribute the advanced Dragonfly(TM)* pancreaticobiliary system from Dragonfly Endoscopy, Inc. in the United States. This innovative platform introduces significant enhancements in pancreaticobiliary endoscopy - a field where procedural standards have remained largely unchanged for decades. Financial terms of the agreement were not disclosed.

In March 2025, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS(TM) Intravascular Ultrasound System. An investigational technology, the TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation (RDN) for hypertension.

In December 2024, Abbott Laboratories and DexCom said that they have reached an agreement to settle all patent disputes between them related to continuous glucose monitoring devices. The agreement will dismiss all pending cases in courts and patent offices worldwide, along with a provision preventing legal action between the companies for patent and appearance disputes for the next 10 years.

Products Covered:

• Deep Brain Stimulator
• Vagus Nerve Stimulation
• Responsive Neurostimulation

Applications Covered:

• Chronic Pain
• Epilepsy
• Parkinson's Disease
• Depression
• Alzheimer's Disease
• Essential Tremor
• Other Applications

End Users Covered:

• Hospitals
• Neurology Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Brain Implants Market, By Product

• 5.1 Introduction
• 5.2 Deep Brain Stimulator
• 5.3 Vagus Nerve Stimulation
• 5.4 Responsive Neurostimulation

6 Global Brain Implants Market, By Application

• 6.1 Introduction
• 6.2 Chronic Pain
• 6.3 Epilepsy
• 6.4 Parkinson's Disease
• 6.5 Depression
• 6.6 Alzheimer's Disease
• 6.7 Essential Tremor
• 6.8 Other Applications

7 Global Brain Implants Market, By End User

• 7.1 Introduction
• 7.2 Hospitals
• 7.3 Neurology Clinics
• 7.4 Other End Users

8 Global Brain Implants Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Boston Scientific Corporation
• 10.2 Medtronic plc
• 10.3 Synchron Inc.
• 10.4 Abbott Laboratories
• 10.5 NeuroPace, Inc.
• 10.6 LivaNova Plc
• 10.7 Precision Neuroscience Inc
• 10.8 NDI Medical LLC
• 10.9 Renishaw PLC
• 10.10 Aleva Neurotherapeutics SA
• 10.11 Beijing PINS Medical Co., Ltd
• 10.12 Functional Neuromodulation, Ltd.
• 10.13 SceneRay Co., Ltd
• 10.14 Cyberonics, Inc.
• 10.15 NeuroSigma Inc